Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 8/20 | 0.47 |
| ▸ | GPR183 | P32249 | 7/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.47 |
| ▸ | TSHR | P16473 | 5/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25301235 | 0.89 | USP2 (0.43) | USP2CYP2D6CYP3A4TSHRCYP1A2 | |
| SCHEMBL25255747 | 0.86 | CYP2D6 (0.48) | USP2CYP2D6CYP3A4TSHRCYP1A2 | |
| SCHEMBL25254915 | 0.85 | RORC (0.46) | GPR183CYP2D6CYP3A4TSHRTEAD1 | |
| SCHEMBL25299011 | 0.84 | LMNA (0.54) | USP2GPR183CYP2D6CYP3A4TSHR | |
| SCHEMBL31308021 | 0.82 | TEAD1 (0.47) | USP2GPR183CYP2D6CYP3A4TSHR | |
| SCHEMBL25146101 | 0.81 | MGLL (0.40) | USP2GPR183CYP2D6CYP3A4TSHR | |
| SCHEMBL25145630 | 0.80 | TEAD1 (0.47) | USP2CYP2D6CYP3A4TSHRCYP1A2 | |
| SCHEMBL25248261 | 0.80 | PPARD (0.51) | USP2GPR183CYP2D6CYP3A4TSHR | |
| SCHEMBL2381838 | 0.79 | CYP2D6 (0.67) | USP2CYP2D6CYP3A4TSHRCYP1A2 | |
| SCHEMBL30409734 | 0.79 | MGLL (0.39) | USP2GPR183CYP2D6CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981661-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4208456-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2023-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11981661-B2 | Heterocyclic compounds | CBR3, BRIX1, CCNY | USP2 3410/4885GPR183 1629/4885CYP2D6 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.